Form 4: Alnylam CEO Yvonne Greenstreet Reports Stock Transactions Following PSU Vesting
SEC Form 4
Alnylam Pharmaceuticals' CEO, Yvonne Greenstreet, reports acquisition and disposal of company stock following the vesting of performance-based stock units (PSUs) and subsequent sell-to-cover transactions.
Summary
- On June 24, 2024, Yvonne Greenstreet, CEO of Alnylam Pharmaceuticals, acquired 16,953 shares of common stock upon the vesting of a portion of performance-based stock units (PSUs) granted in February 2022.
- The vesting was triggered by Alnylam's public reporting of positive results from a Phase 3 clinical study in ATTR amyloidosis with cardiomyopathy.
- On June 25, 2024, Greenstreet sold a total of 8,398 shares of common stock at prices ranging from $221.71 to $235.73 per share.
- These sales were executed to cover minimum statutory tax withholding obligations related to the vesting of the PSUs.
- Following these transactions, Greenstreet directly owns 80,534 shares and indirectly owns 407 shares through a managed account.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The vesting of PSUs suggests the company met certain performance targets, which is a positive signal. The subsequent stock sales are a standard procedure for covering tax obligations and do not necessarily indicate a negative outlook from the CEO.
Positives
- The vesting of PSUs indicates the achievement of performance goals related to a positive clinical trial outcome.
- The positive clinical trial results likely contributed to the stock price at which the shares were sold.
Industry Context
This filing reflects standard executive compensation practices in the pharmaceutical industry, where stock options and PSUs are used to align executive incentives with company performance and shareholder value. The sell-to-cover transactions are a common occurrence when equity awards vest.
Comparison to Industry Standards
- Executive compensation packages including PSUs are common in the pharmaceutical industry, with companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilizing similar incentive structures.
- Sell-to-cover practices are standard across industries to manage tax obligations arising from equity compensation.
Stakeholder Impact
- Shareholders may view the PSU vesting as a positive sign of company performance.
- The stock sales could have a minor, temporary impact on the stock price.
Key Dates
| Date | Description |
|---|---|
| February 23, 2022 | Reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. |
| June 24, 2024 | Shares issued to reporting person upon vesting of one-third of the shares subject to the PSU. |
| June 25, 2024 | Shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision. |
| June 26, 2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.